Risk factors for cardiovascular disease in systemic lupus erythematosus

被引:398
|
作者
Svenungsson, E [1 ]
Jensen-Urstad, K
Heimbürger, M
Silveira, A
Hamsten, A
de Faire, U
Witztum, JL
Frostegård, J
机构
[1] Karolinska Hosp, Dept Rheumatol, S-17176 Stockholm, Sweden
[2] Karolinska Hosp, Ctr Mol Med, S-17176 Stockholm, Sweden
[3] Karolinska Hosp, Dept Clin Physiol, S-17176 Stockholm, Sweden
[4] Karolinska Hosp, Dept Cardiol, S-17176 Stockholm, Sweden
[5] Karolinska Hosp, King Gustaf V Res Inst, S-17176 Stockholm, Sweden
[6] Huddinge Univ Hosp, Dept Rheumatol, S-14186 Huddinge, Sweden
[7] Karolinska Inst, Karolinska Hosp, Dept Med, Cardiovasc Lab, S-10401 Stockholm, Sweden
[8] Karolinska Inst, Karolinska Hosp, Inst Environm Med, S-10401 Stockholm, Sweden
[9] Karolinska Inst, Karolinska Hosp, Div Cardiovasc Epidemiol, S-10401 Stockholm, Sweden
[10] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
关键词
cardiovascular diseases; risk factors; atherosclerosis; ultrasonics;
D O I
10.1161/hc4101.097518
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Cardiovascular disease (CVD) is overrepresented in patients with systemic lupus erythematosus (SLE). We determined the prevalence of traditional and nontraditional risk factors for CVD in SLE patients with and without CVD compared with controls. Methods and Results-Twenty-six women (aged 52 +/-8.2 years) with SLE and a history of CVD (SLE cases) were compared with 26 age-matched women with SLE but without manifest CVD (SLE controls) and 26 age-matched population-based control women (population controls). Common carotid intima-media thickness (IMT) was measured by B-mode ultrasound as a surrogate measure of atherosclerosis. SLE cases had increased IMT compared with SLE controls (P=0.03) and population controls (P=0.001), whereas IMT of SLE controls did not differ from population controls. SLE cases had raised plasma concentrations of circulating oxidized LDL (OxLDL; P=0.03), as measured by the monoclonal antibody EO6, and autoantibodies to epitopes of OxLDL (P <0.001); dyslipidemia with raised triglycerides (P<0.001) and lipoprotein(a) (P=0.002) and decreased HDL-cholesterol concentrations (P=0.03); raised a-l-antitrypsin (P=0.002), lupus anticoagulant (P=0.007), and homocysteine levels (P=0.03); more frequent osteoporosis (P=0.03); and a higher cumulative prednisolone dose (P=0.05) compared with SLE controls. Disease duration, smoking, blood pressure, body mass index, and diabetes mellitus did not differ significantly between the groups. Conclusions-A set of distinct CVD risk factors separate SLE cases from SLE controls and population controls. If confirmed in a prospective study, they could be used to identify SLE patients at high risk for CVD in order to optimize treatment.
引用
收藏
页码:1887 / 1893
页数:7
相关论文
共 50 条
  • [41] Therapy Insight: systemic lupus erythematosus as a risk factor for cardiovascular disease
    Sahena Haque
    Ian N Bruce
    [J]. Nature Clinical Practice Cardiovascular Medicine, 2005, 2 : 423 - 430
  • [42] CARDIOVASCULAR RISK PROFILE IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Monova, D.
    Monov, S.
    Rashkov, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 185 - 186
  • [43] Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease
    Haque, S
    Bruce, IN
    [J]. NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2005, 2 (08): : 423 - 430
  • [44] Cardiovascular disease in systemic lupus erythematosus: an update
    Liu, Yudong
    Kaplan, Mariana J.
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2018, 30 (05) : 441 - 448
  • [45] Epidemiology of cardiovascular disease in systemic lupus erythematosus
    Aranow, C
    Ginzler, EM
    [J]. LUPUS, 2000, 9 (03) : 166 - 169
  • [46] Systemic lupus erythematosus complicated with cardiovascular disease
    Lu, Ke-Qu
    Zhu, Zhen-Zhen
    Wei, Si-Ru
    Zeng, Hua-Song
    Mo, Han-You
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (08) : 1429 - 1431
  • [47] Cardiovascular Disease Disparities in Systemic Lupus Erythematosus
    Duarte-Garcia, Ali
    Yazdany, Jinoos
    [J]. JOURNAL OF RHEUMATOLOGY, 2023, 50 (01) : 9 - 10
  • [48] Cardiovascular disease complications in systemic lupus erythematosus
    Torres, Alexander
    Askari, Ali D.
    Malemud, Charles J.
    [J]. BIOMARKERS IN MEDICINE, 2009, 3 (03) : 239 - 252
  • [49] Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus
    Sivakumaran, Jagan
    Harvey, Paula
    Omar, Ahmed
    Tayer-Shifman, Oshrat
    Urowitz, Murray B.
    Gladman, Dafna D.
    Anderson, Nicole
    Su, Jiandong
    Touma, Zahi
    [J]. LUPUS SCIENCE & MEDICINE, 2021, 8 (01):
  • [50] Prevalence and correlation of conventional and lupus-specific risk factors for cardiovascular disease in Chinese systemic lupus erythematosus patients
    Yang, L.
    Tao, J.
    Tang, X.
    Wang, Y.
    He, X.
    Xu, G.
    Ren, Y.
    Tu, Y.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2012, 26 (01) : 95 - 101